Cidara Therapeutics, Inc. (NASDAQ:CDTX) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.73) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.94) by $0.21, Bloomberg Earnings reports.

Cidara Therapeutics (NASDAQ:CDTX) traded down $0.30 during midday trading on Thursday, hitting $7.65. The stock had a trading volume of 92,275 shares, compared to its average volume of 82,129. Cidara Therapeutics has a one year low of $5.60 and a one year high of $11.85. The company has a quick ratio of 7.49, a current ratio of 7.49 and a debt-to-equity ratio of 0.15.

A number of equities research analysts recently weighed in on CDTX shares. WBB Securities raised Cidara Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Zacks Investment Research cut Cidara Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $15.00 price target on shares of Cidara Therapeutics in a report on Tuesday, September 26th. ValuEngine raised Cidara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, July 14th. Finally, HC Wainwright raised their price target on Cidara Therapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Cidara Therapeutics currently has a consensus rating of “Buy” and an average price target of $13.39.

In other news, CEO Jeffrey Stein bought 7,350 shares of the stock in a transaction dated Tuesday, September 12th. The stock was bought at an average cost of $6.79 per share, with a total value of $49,906.50. Following the purchase, the chief executive officer now owns 51,851 shares of the company’s stock, valued at $352,068.29. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 18.90% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Cidara Therapeutics, Inc. (CDTX) Announces Earnings Results, Beats Expectations By $0.21 EPS” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/09/cidara-therapeutics-inc-cdtx-announces-earnings-results-beats-expectations-by-0-21-eps.html.

About Cidara Therapeutics

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Earnings History for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Stock Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related stocks with our FREE daily email newsletter.